RIGL Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 0.91%. Rigel Pharmaceuticals, Inc.'s return on equity of 299.43% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.20, signalling upside risk potential of 85.98%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.272, which suggesting that the stock is 27.172% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Rigel Pharmaceuticals, Inc.'s net income of $268.1M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.46x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 1.77x versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -4.77%. Rigel Pharmaceuticals, Inc.'s return on equity of 299.43% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.20, signalling upside risk potential of 85.98%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $6.10 which suggests that it could grow by 72.32%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.272, which suggesting that the stock is 27.172% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.166, suggesting its less volatile than the S&P 500 by 83.384%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.8M, which are larger than Ironwood Pharmaceuticals, Inc. quarterly revenues of $47.7M. Rigel Pharmaceuticals, Inc.'s net income of $268.1M is higher than Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.46x while Ironwood Pharmaceuticals, Inc.'s PE ratio is 26.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 1.77x versus 1.83x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 34.4%. Rigel Pharmaceuticals, Inc.'s return on equity of 299.43% beat Eli Lilly & Co.'s return on equity of 104.39%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.20, signalling upside risk potential of 85.98%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rigel Pharmaceuticals, Inc. has a beta of 1.272, which suggesting that the stock is 27.172% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Rigel Pharmaceuticals, Inc.'s net income of $268.1M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.46x while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 1.77x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -165.45%. Rigel Pharmaceuticals, Inc.'s return on equity of 299.43% beat Nektar Therapeutics's return on equity of -364.32%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.20, signalling upside risk potential of 85.98%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 66.42%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Nektar Therapeutics.

Rigel Pharmaceuticals, Inc. has a beta of 1.272, which suggesting that the stock is 27.172% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.8M, which are larger than Nektar Therapeutics quarterly revenues of $21.8M. Rigel Pharmaceuticals, Inc.'s net income of $268.1M is higher than Nektar Therapeutics's net income of -$36.1M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 1.46x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 1.77x versus 93.68x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.